en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6908.com › Wiki › Research History And Clinical Assessment — Questions and Answers

Research History And Clinical Assessment — Questions and Answers

By Editorial Desk · published 2025-07-14 · last reviewed 2025-08-29 · Wiki

thymus extract comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Molecular Structure and Biological Background

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Related pages on this site

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Background from the literature

=== Sublingual administration === Estradiol tablets can be taken sublingually instead of orally. Non-micronized estradiol tablets in doses of 0.125, 0.25, and 1 mg were previously marketed for use by sublingual administration under brand names such as Diogynets, Estradiol Membrettes, and Dimenformon in the 1950s. Non-micronized estradiol has poor water solubility, but micronized estradiol is rapidly absorbed by the sublingual route. All oral estradiol tablets are micronized, as this improves the efficiency of estradiol absorption in the gastrointestinal tract. Likewise, all oral estradiol valerate tablets seem to be micronized. The sublingual route is, in actuality, probably a combination of sublingual and oral delivery of estradiol due to incidental swallowing of some of the estradiol. The absorption of sublingual estradiol can be attributed to the rich vascularization under the tongue. With administration of an oral estradiol tablet sublingually, complete dissolution of the tablet occurs within a few minutes and circulating levels of estradiol begin to rise within 5 minutes. Maximal levels of estradiol occur after 30 to 60 minutes of administration. After this, estradiol levels drop steeply within 4 hours, and this is followed by a more gradual decline in levels of estradiol and a return to baseline concentrations by 24 hours. The rapid rise and steep fall of estradiol levels with sublingual administration of estradiol is analogous to the case of intravenous injection and intranasal administration of the hormone.

An extension of the WAG algorithm is used, with a new PhyML (WAG+Γ4) model taking into account of sites with different evolutionary rates. Qmaker and nQmaker (2021, 2022), programs with the ability to estimate time-reversible and nonreversible matrices from very large datasets quickly. Each provide a general matrix and 5 specialized matrices, for a total of 12 precalculated substitution matrices. Matrices using a selection of proteins based on structural relatedness, as proposed by Benner et al. (1994), Fan (2004), and Steven et al. (2004). Matrices using structural alignments of proteins instead of simple sequence alignment (6 separate publications). Matrices using known physiochemical parameters of amino acid residues (5 separate publications). For a list of more models (including irreversible i.e. asymmetric and/or specialized ones), see the documentation for recent bioinformatic software including IQ-Tree, PhyML, and RAxML.

The West Bengal Police has jurisdiction concurrent with the twenty-two revenue districts of the State (excluding the metropolitan city of Kolkata) which comprises one of the two general police districts of West Bengal under the Police Act 1861. The other general police district consists of the major portions of the metropolitan area of Kolkata, and has a separate police force (Kolkata Police Commissionerate) constituted and administered under the Calcutta Police Act 1866 & Calcutta (Suburban Police) Act 1866. This arrangement, unique in India, was conceived during colonial times when Calcutta was the capital of British India. The city police have been kept independent of the state police force.

== Phase 1 == The first phase of the Protein Structure Initiative (PSI-1) lasted from June 2000 until September 2005, and had a budget of $270 million funded primarily by NIGMS with support from the National Institute of Allergy and Infectious Diseases. PSI-1 saw the establishment of nine pilot centers focusing on structural genomics studies of a range of organisms, including Arabidopsis thaliana, Caenorhabditis elegans and Mycobacterium tuberculosis. During this five-year period over 1,100 protein structures were determined, over 700 of which were classified as "unique" due to their < 30% sequence similarity with other known protein structures. The primary goal of PSI-1, to develop methods to streamline the structure determination process, resulted in an array of technical advances. Several methods developed during PSI-1 enhanced expression of recombinant proteins in systems like Escherichia coli, Pichia pastoris and insect cell lines. New streamlined approaches to cell cloning, expression and protein purification were also introduced, in which robotics and software platforms were integrated into the protein production pipeline to minimize required manpower, increase speed, and lower costs.

In 2024, Romania had a GDP (PPP) of around $894 billion and a GDP per capita (PPP) of $47,203. According to the World Bank, Romania is a high-income economy. According to Eurostat, Romania's GDP per capita (PPS) was 77% of the EU average (100%) in 2022, an increase from 44% in 2007 (the year of Romania's accession to the EU), making Romania one of the fastest growing economies in the EU. The Bucharest Stock Exchange (BVB) is the stock exchange of Romania, located in Bucharest. In 2024, the BVB boasted a $74 billion market capitalisation and a trading volume of $7.2 billion. As of 2024, 86 companies were listed on the exchange. In September 2020, FTSE Russell upgraded the BVB from a Frontier market to a Secondary Emerging Market.

Sources: en.wikipedia.org

Further detail

In Indonesia, the government supports public universities in each province. Funding comes through the Ministry of Education, Culture, Research, and Technology and the provincial and municipal governments.

Chestnuts can vary widely in shade and different terms are sometimes used to describe these shades, even though they are genetically indistinguishable. Collectively, these coat colors are usually called "red" by geneticists.

=== Precautions === Excessive consumption of parsley should be avoided by pregnant women. Normal food quantities are safe for pregnant women, but consuming excessively large amounts may have uterotonic effects.

For his contributions to the development and progress of Malaysia, Mahathir was honoured by his successor, Abdullah Badawi, with the title Bapa Pemodenan Malaysia (Father of Malaysia's Modernisation) after stepping down from office. The following year, Barisan Nasional leaders and members paid tribute to Mahathir during a dinner in Kuala Lumpur, acknowledging his remarkable contributions to the coalition and the nation.

Sources: en.wikipedia.org

Background from the literature

=== Pharmacokinetics === Meclizine reaches peak plasma concentration in about 1.5 hours and has an elimination half-life of 5–6 hours. Despite its relatively short half-life, the drug is reported to remain effective for motion sickness for 12 – 24 hours. Meclizine has low bioavailability (22–32%) and a delayed onset to action in part due to its poor solubility in water (0.1 mg/ml) and gastrointestinal fluid. In children it has been found that taking meclizine with food increases its bioavailability slightly. It is metabolized in the liver by the CYP2D6 enzyme. Ten metabolites have been identified. In rats, the main metabolite is norchlorcyclizine, which distributes extensively through body tissue.

Wheeler was awarded the Lab on a Chip Pioneers in Miniaturization Award (2017), an E.W.R. Steacie Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC) (2015), a Connaught Foundation McLean Fellowship (2014), the Joseph Black Award from the Royal Society of Chemistry (2012), the Arthur F. Findeis Award from the American Chemical Society (2012), the Young Innovator Award in Analytical Chemistry (2011), and a Sloan Research Fellowship (2009). In January 2024, Wheeler was honored with the Ricardo Aroca Award, recognizing his contributions to analytical chemistry and advancing lab-on-a-chip techniques, particularly through the use of digital microfluidics (DMF), which enables precise manipulation of liquid droplets on electrode arrays. The Award is bestowed upon a scientist living in Canada who has made a notable contribution to the discipline of analytical chemistry while conducting research within the country.

German chemists Walter Noddack, Otto Berg, and Ida Tacke reported the discovery of element 75 and element 43 in 1925, and named element 43 masurium (after Masuria in eastern Prussia, now in Poland, the region where Walter Noddack's family originated). This name caused significant resentment in the scientific community, because it was interpreted as referring to a series of victories of the German army over the Russian army in the Masuria region during World War I; as the Noddacks remained in their academic positions while the Nazis were in power, suspicions and hostility against their claim for discovering element 43 continued. The group bombarded columbite with a beam of electrons and deduced element 43 was present by examining X-ray emission spectrograms. The wavelength of the X-rays produced is related to the atomic number by a formula derived by Henry Moseley in 1913. The team claimed to detect a faint X-ray signal at a wavelength produced by element 43. Later experimenters could not replicate the discovery, and it was dismissed as an error. Still, in 1933, a series of articles on the discovery of elements quoted the name masurium for element 43. Some more recent attempts have been made to rehabilitate the Noddacks' claims, but they are disproved by Paul Kuroda's study on the amount of technetium that could have been present in the ores they studied: it could not have exceeded 3 × 10−11 μg/kg of ore, and thus would have been undetectable by the Noddacks' methods.

In this study, a multicenter, randomized, active-controlled, parallel group, open-label, exploratory study was designed to evaluate the efficacy on glycemic variability and safety of initial combination therapy of gemigliptin 50 mg qd versus sitagliptin 100 mg qd, or glimepiride 2 mg qd with metformin in patients with T2DM (study identifier: LG-DPCL012, STABLE study; ClinicalTrials.gov registration number: NCT01890629). The mean amplitude of glycemic excursions (MAGE) and SD of glucose were used for assessing glucose fluctuations from the baseline after 12 weeks of treatment. At 12 weeks, MAGE was significantly lower in the DPP-4 inhibitor groups (gemigliptin and sitagliptin) than in the glimepiride group (–43.1, –38.3, and –21.7 mg/dL, respectively). Furthermore, the SD of mean glucose was significantly lower in patients with gemigliptin when compared with sitagliptin (P=0.023) and glimepiride (P=0.0058). Ongoing studies Several clinical studies in LG Life Sciences are actively underway to assess the efficacy and safety as an add-on combination therapy with insulin (with or without metformin) (ClinicalTrials.gov registration number: NCT02831361), to evaluate the efficacy and safety of gemigliptin-rosuvastatin fixed-dose combination in patients with T2DM and dyslipidemia in phase III clinical trials (ClinicalTrials.gov registration number: NCT02126358), and to evaluate the efficacy and safety of gemigliptin compared with vildagliptin in Russian patients with T2DM (ClinicalTrials.gov registration number: NCT02343926).

== Link to ketogenic diet == One controlled study kept mice on a ketogenic diet and measured kynurenic acid concentrations in different parts of the brain. It found that the mice on the ketogenic diet had greater kynurenic acid concentrations in the striatum and hippocampus compared to mice on a normal diet, with no significant difference in the cortex. In response to the studies showing detrimental behaviour following increases in kynurenic acid the authors also note that the diet was generally well tolerated by the animals, with no "gross behavioural abnormalities". They posit that the increases in concentrations found were insufficient to produce behavioural changes seen in those studies.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

Is thymosin alpha-1 a naturally occurring hormone?

It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.

Network